TY - JOUR
T1 - Perfil de miARNs séricos como una potencial herramienta para el diagnóstico de cáncer gástrico no invasivo en pacientes mexicanos
AU - Cuellar-Gomez, Hugo
AU - Ocharán-Hernández, Ma Esther
AU - Calzada-Mendoza, Claudia C.
AU - Comoto-Santacruz, David A.
N1 - Publisher Copyright:
© 2020 Academia Mexicana de Cirugía. Published by Permanyer. This is an open access article under the terms of the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
PY - 2021/11
Y1 - 2021/11
N2 - Introduction: Gastric cancer (GC) is the third leading cause of cancer death and a major public health-care problem worldwide. At present, methods for plasma detection of cancer are limited. MicroRNAs (miRNAs) have recently been proposed as genetic regulators, which are deregulated in different types of cancer. The miRNAs are stable in serum/plasma and can be detected. Circulating miRNAs in plasma have been proposed as potential diagnostic biomarkers in GC. Materials and methods: After reviewing the relevant literature, the expression levels of seven miRNAs (miR-16, miR-21, miR-25, miR-26a, miR-92, miR-218, miR-223, and miR-451) were assessed by quantitative reverse transcription polymerase chain reaction using TaqMan microRNA Assays (Applied Biosystems) in plasma samples from GC patients (n = 80) and healthy controls (n = 80). Results: Our results demonstrated that the expression levels of miR-21 and miR-25 were significantly upregulated in GC patients compared to healthy controls with a Fold Change of 11.551 and 60.129, respectively, while miR-223 showed downregulation in GC patients compared to healthy controls with a Fold Change of −247.281. The absolute value of Fold Change > 2 was consider significant, p < 0.05. Conclusions: Our results indicated that miR-21, miR-25, and miR-223 in plasma samples can be served as a potential noninvasive tool in detection of GC.
AB - Introduction: Gastric cancer (GC) is the third leading cause of cancer death and a major public health-care problem worldwide. At present, methods for plasma detection of cancer are limited. MicroRNAs (miRNAs) have recently been proposed as genetic regulators, which are deregulated in different types of cancer. The miRNAs are stable in serum/plasma and can be detected. Circulating miRNAs in plasma have been proposed as potential diagnostic biomarkers in GC. Materials and methods: After reviewing the relevant literature, the expression levels of seven miRNAs (miR-16, miR-21, miR-25, miR-26a, miR-92, miR-218, miR-223, and miR-451) were assessed by quantitative reverse transcription polymerase chain reaction using TaqMan microRNA Assays (Applied Biosystems) in plasma samples from GC patients (n = 80) and healthy controls (n = 80). Results: Our results demonstrated that the expression levels of miR-21 and miR-25 were significantly upregulated in GC patients compared to healthy controls with a Fold Change of 11.551 and 60.129, respectively, while miR-223 showed downregulation in GC patients compared to healthy controls with a Fold Change of −247.281. The absolute value of Fold Change > 2 was consider significant, p < 0.05. Conclusions: Our results indicated that miR-21, miR-25, and miR-223 in plasma samples can be served as a potential noninvasive tool in detection of GC.
KW - Biomarker
KW - Diagnosis
KW - Gastric cancer
KW - MicroRNAs
KW - Plasma
UR - http://www.scopus.com/inward/record.url?scp=85121668456&partnerID=8YFLogxK
U2 - 10.24875/CIRU.20000963
DO - 10.24875/CIRU.20000963
M3 - Artículo
C2 - 34851581
AN - SCOPUS:85121668456
SN - 0009-7411
VL - 89
SP - 748
EP - 754
JO - Cirugia y Cirujanos (English Edition)
JF - Cirugia y Cirujanos (English Edition)
IS - 6
ER -